Abstract:1631 Objectives: Parkinson’s disease (PD) is a neurodegenerative disorder characterized by the degeneration of dopaminergic neurons in the substantia nigra of the brain. Stem cell therapy holds great promise as a potential treatment strategy to produce functional neurons from human pluripotent stem cells (PSCs). A strategy of using PSC-derived dopamine neurons modified to express active or inhibitory forms of DREADD (designer receptors exclusively activated by designer drugs) has been developed to evaluate therapeutic potential for PD treatment in the rhesus monkey model. PET radiotracers of [C-11]clozapine and [C-11]raclopride were used to investigate alterations in binding patterns in the endogenous dopamine competition following treatment with the exogenous designer drug clozapine-N-oxide (CNO). Methods: Five rhesus monkeys underwent a unilateral intracarotid artery injection of MPTP targeting the right substantia nigra or putamen. All monkeys received unilateral intracerebral injections of PSCs with guidance from real-time intraoperative magnetic resonance imaging (RT-IMRI) performed in a 3-T GE SIGNA MRI scanner. Daily doses of CNO were administered to the monkeys to activate the DREADDs expressed by the PSC-derived neurons. Four monkeys underwent [C-11]clozapine scans and one monkey underwent a [C-11]raclopride scan on a microPET Focus 220 scanner. Dynamic data were acquired for 90 minutes post-injection of [C-11]clozapine, and a 120 minute bolus+infusion scan of [C-11]raclopride to assess dopamine release during CNO activation. Regions of interest (ROIs) were drawn for the left putamen, right putamen and cerebellum. Time activity curves (TACs) were generated for each ROI for a semi-quantitative comparison of bilateral differences in putamen uptake following treatment. Results: Asymmetries between the left and right putamen were noticed in the PET data for the [C-11]clozapine scans. Two monkeys showed unilateral uptake of radiotracer with no uptake in the right putamen. The remaining showed bilateral uptake of radiotracer in both the left and right putamen following treatment. The [C-11]raclopride results showed bilateral uptake of radiotracer with elevated uptake in the right putamen following the administration of CNO indicating alteration in dopaminergic function. Conclusions: These qualitative results show the potential for evaluation of PSC-derived neuronal function using PET methodologies. The semi-quantitative analysis will be confirmed through histology studies to show the precise location and effectiveness of PSC engraftment at restoring neuronal function.

Update Lessons from Positron Emission Tomography Imaging Part I: A Systematic Critical Review on Therapeutic Plasma Concentrations of Antipsychotics

Update Lessons from PET Imaging Part II: A Systematic Critical Review on Therapeutic Plasma Concentrations of Antidepressants

Optimisation of pharmacotherapy in psychiatry through therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests: Focus on antipsychotics

Clinical Pharmacokinetics of Atypical Antipsychotics: An Update

Molecular imaging in patients with mood disorders: a review of PET findings

The use of PET imaging in studying cognition, genetics and pharmacotherapeutic interventions in schizophrenia

International Consensus on Clinical Use of Presynaptic Dopaminergic Positron Emission Tomography Imaging in Parkinsonism.

Therapeutic Reference Ranges for Psychotropic Drugs: A Protocol for Systematic Reviews

Progress on the Application of Positron Emission Tomography Imaging of Cannabinoid Type 1 Receptor in Neuropsychiatric Diseases.

PET‐MRI Applications and Future Prospects in Psychiatry

A Comparative Proteomics Analysis of Rat Mitochondria from the Cerebral Cortex and Hippocampus in Response to Antipsychotic Medications

Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants

Occupancy of Central Neurotransmitter Receptors by Risperidone, Clozapine and Haloperidol, Measured Ex Vivo by Quantitative Autoradiography

Imaging Metabotropic Glutamate Receptor System: Application of Positron Emission Tomography Technology in Drug Development

Using PET Methods to Evaluate Induced Pluripotent Stem Cell-Derived Neuronal Function

Update on novel antipsychotics and pharmacological strategies for treatment-resistant schizophrenia

Challenging pharmacotherapy management of a psychotic disorder due to a delicate pharmacogenetic profile and drug-drug interactions: a case report and literature review

Current Status of Therapeutic Drug Monitoring in Mental Health Treatment: A Review

[Therapeutic drug monitoring of antipsychotic drugs in routine psychiatric practice]

Development of a UPLC-MS/MS method for routine therapeutic drug monitoring of aripiprazole, amisulpride, olanzapine, paliperidone and ziprasidone with a discussion of their therapeutic reference ranges for Chinese patients

Current Applications of PET/MR: Part II: Clinical Applications II